GlassScriptPhysician profile
Daesman N Suri
NPI 1134186968
$1,363.74
in general payments reported to CMS, 2019-2025
22 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $41.40 · 2023: $247 · 2024: $594 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $399.76 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $236.74 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sequel Med Tech, LLC | $85.23 | 2025 | Twiist |
| Dexcom, INC. | $75.91 | 2023-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $67.66 | 2024 | Gvoke Hypopen |
| Pfizer INC. | $64.49 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.45 | 2021-2024 | Synjardy, Jardiance, Tradjenta |
| Abbott Laboratories | $53.32 | 2024-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $47.63 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sanofi-Aventis U.S. LLC | $38.28 | 2023 | |
| Amneal Pharmaceuticals LLC | $32.55 | 2023-2024 | Unithroid |
| Amphastar Pharmaceuticals, INC. | $22.12 | 2024 | |
| Axsome Therapeutics, INC. | $21.60 | 2025 | Symbravo |
| Exact Sciences Corporation | $20.29 | 2025 | Cologuard Collection Kit |
| Insulet Corporation | $20.16 | 2023 | Omnipod |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.86 | 2021 | |
| Tandem Diabetes Care, INC. | $19.00 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Glaxosmithkline, LLC. | $18.68 | 2024 | Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.55 | 2024 | Xifaxan |
| Ibsa Pharma INC. | $17.30 | 2025 | Flector, Licart, Tirosint |
| Embecta Corp. | $13.42 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Theracosbio, LLC | $10.74 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daesman Suri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.